Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score

Sung-Gu Kang, C. H. Park, D. K. Kim, J. K. Park, S. J. Hong, B. H. Chung, C. S. Kim, K. S. Lee, J. C. Kim, Jeong Gu Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims: To evaluate long-term outcome of tamsuolsin 0.2 mg for benign prostatic hyperplasia (BPH) patients using a new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS) over a 48-week period. Methods: This study investigated the long-term outcomes of either well-responded or poorly responded patient group as defined by LOS at the period of 12 weeks after BPH treatment. Outcome parameters used in this study were the most bothersome symptoms, BPH K1-short form as well as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and postvoiding residual urine volume at 24-, 36- and 48-week follow-up. Results: Of the 414 patients recruited initially, 310 (75.2%) were defined as the responders and 39 (9.5%) as the non-responders to the treatment at 12 weeks, which was stratified by LOS. In this long-term study, the differences in improvement rates of clinical parameters between responder and non-responder groups at 12 weeks of treatment were maintained over the period of 48 weeks. Among the responder patients, most (75.6%) chose continuous administrations of tamsulosin. Improvements in clinical parameters were maintained in this subgroup. It is noteworthy that the improvements in clinical parameters of the non-responder group were dismal despite switching to the other treatment modalities. Conclusions: Long-term tamsuolsin 0.2 mg for BPH patients is an effective treatment, both subjectively and objectively. Considering its integrative nature, LOS seemed to be one of the useful tools to predict the outcome after the management of LUTS.

Original languageEnglish
Pages (from-to)691-697
Number of pages7
JournalInternational Journal of Clinical Practice
Volume65
Issue number6
DOIs
Publication statusPublished - 2011 Jun 1

Fingerprint

tamsulosin
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Therapeutics
Residual Volume
Prostate
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score. / Kang, Sung-Gu; Park, C. H.; Kim, D. K.; Park, J. K.; Hong, S. J.; Chung, B. H.; Kim, C. S.; Lee, K. S.; Kim, J. C.; Lee, Jeong Gu.

In: International Journal of Clinical Practice, Vol. 65, No. 6, 01.06.2011, p. 691-697.

Research output: Contribution to journalArticle

@article{5f562e8256404426899bb320ed88a51a,
title = "Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score",
abstract = "Aims: To evaluate long-term outcome of tamsuolsin 0.2 mg for benign prostatic hyperplasia (BPH) patients using a new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS) over a 48-week period. Methods: This study investigated the long-term outcomes of either well-responded or poorly responded patient group as defined by LOS at the period of 12 weeks after BPH treatment. Outcome parameters used in this study were the most bothersome symptoms, BPH K1-short form as well as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and postvoiding residual urine volume at 24-, 36- and 48-week follow-up. Results: Of the 414 patients recruited initially, 310 (75.2{\%}) were defined as the responders and 39 (9.5{\%}) as the non-responders to the treatment at 12 weeks, which was stratified by LOS. In this long-term study, the differences in improvement rates of clinical parameters between responder and non-responder groups at 12 weeks of treatment were maintained over the period of 48 weeks. Among the responder patients, most (75.6{\%}) chose continuous administrations of tamsulosin. Improvements in clinical parameters were maintained in this subgroup. It is noteworthy that the improvements in clinical parameters of the non-responder group were dismal despite switching to the other treatment modalities. Conclusions: Long-term tamsuolsin 0.2 mg for BPH patients is an effective treatment, both subjectively and objectively. Considering its integrative nature, LOS seemed to be one of the useful tools to predict the outcome after the management of LUTS.",
author = "Sung-Gu Kang and Park, {C. H.} and Kim, {D. K.} and Park, {J. K.} and Hong, {S. J.} and Chung, {B. H.} and Kim, {C. S.} and Lee, {K. S.} and Kim, {J. C.} and Lee, {Jeong Gu}",
year = "2011",
month = "6",
day = "1",
doi = "10.1111/j.1742-1241.2011.02667.x",
language = "English",
volume = "65",
pages = "691--697",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score

AU - Kang, Sung-Gu

AU - Park, C. H.

AU - Kim, D. K.

AU - Park, J. K.

AU - Hong, S. J.

AU - Chung, B. H.

AU - Kim, C. S.

AU - Lee, K. S.

AU - Kim, J. C.

AU - Lee, Jeong Gu

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Aims: To evaluate long-term outcome of tamsuolsin 0.2 mg for benign prostatic hyperplasia (BPH) patients using a new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS) over a 48-week period. Methods: This study investigated the long-term outcomes of either well-responded or poorly responded patient group as defined by LOS at the period of 12 weeks after BPH treatment. Outcome parameters used in this study were the most bothersome symptoms, BPH K1-short form as well as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and postvoiding residual urine volume at 24-, 36- and 48-week follow-up. Results: Of the 414 patients recruited initially, 310 (75.2%) were defined as the responders and 39 (9.5%) as the non-responders to the treatment at 12 weeks, which was stratified by LOS. In this long-term study, the differences in improvement rates of clinical parameters between responder and non-responder groups at 12 weeks of treatment were maintained over the period of 48 weeks. Among the responder patients, most (75.6%) chose continuous administrations of tamsulosin. Improvements in clinical parameters were maintained in this subgroup. It is noteworthy that the improvements in clinical parameters of the non-responder group were dismal despite switching to the other treatment modalities. Conclusions: Long-term tamsuolsin 0.2 mg for BPH patients is an effective treatment, both subjectively and objectively. Considering its integrative nature, LOS seemed to be one of the useful tools to predict the outcome after the management of LUTS.

AB - Aims: To evaluate long-term outcome of tamsuolsin 0.2 mg for benign prostatic hyperplasia (BPH) patients using a new subjective assessment of patient-reported outcomes and the lower urinary tract symptoms (LUTS) outcome score (LOS) over a 48-week period. Methods: This study investigated the long-term outcomes of either well-responded or poorly responded patient group as defined by LOS at the period of 12 weeks after BPH treatment. Outcome parameters used in this study were the most bothersome symptoms, BPH K1-short form as well as International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and postvoiding residual urine volume at 24-, 36- and 48-week follow-up. Results: Of the 414 patients recruited initially, 310 (75.2%) were defined as the responders and 39 (9.5%) as the non-responders to the treatment at 12 weeks, which was stratified by LOS. In this long-term study, the differences in improvement rates of clinical parameters between responder and non-responder groups at 12 weeks of treatment were maintained over the period of 48 weeks. Among the responder patients, most (75.6%) chose continuous administrations of tamsulosin. Improvements in clinical parameters were maintained in this subgroup. It is noteworthy that the improvements in clinical parameters of the non-responder group were dismal despite switching to the other treatment modalities. Conclusions: Long-term tamsuolsin 0.2 mg for BPH patients is an effective treatment, both subjectively and objectively. Considering its integrative nature, LOS seemed to be one of the useful tools to predict the outcome after the management of LUTS.

UR - http://www.scopus.com/inward/record.url?scp=79956073461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956073461&partnerID=8YFLogxK

U2 - 10.1111/j.1742-1241.2011.02667.x

DO - 10.1111/j.1742-1241.2011.02667.x

M3 - Article

VL - 65

SP - 691

EP - 697

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 6

ER -